

Masanori Noguchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8295761/publications.pdf>

Version: 2024-02-01

94
papers

3,076
citations

126708

33
h-index

174990

52
g-index

95
all docs

95
docs citations

95
times ranked

2530
citing authors

#	ARTICLE	IF	CITATIONS
1	Testicular sarcoidosis with bilateral scrotal swelling. IJU Case Reports, 2020, 3, 12-14.	0.1	7
2	Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial. Cancer Immunology, Immunotherapy, 2020, 69, 847-857.	2.0	15
3	A randomized phase III trial of personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel. Oncology Reports, 2020, 45, 159-168.	1.2	17
4	Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients. International Journal of Oncology, 2020, 56, 1479-1489.	1.4	2
5	Malignant lymphoma of the bladder with bilateral hydronephrosis. Rare Tumors, 2019, 11, 203636131882516.	0.3	1
6	Female urethral diverticulum containing large calculi. Urology Case Reports, 2018, 18, 14-15.	0.1	5
7	Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers. Cancer Science, 2018, 109, 2660-2669.	1.7	10
8	Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: A randomized, double-blind, placebo-controlled, phase 2 trial.. Journal of Clinical Oncology, 2018, 36, 214-214.	0.8	1
9	Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, e385-e394.	1.1	13
10	Immunological evaluation of peptide vaccination for cancer patients with the <sc>HLA</sc> A11⁺ or A33⁺ allele. Cancer Science, 2017, 108, 598-603.	1.7	6
11	Clinical development of immunotherapy for prostate cancer. International Journal of Urology, 2017, 24, 675-680.	0.5	6
12	Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine. Cancer Science, 2017, 108, 2326-2332.	1.7	18
13	Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma. Cancer Science, 2017, 108, 2430-2437.	1.7	14
14	Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer. Journal of Immunology Research, 2016, 2016, 1-7.	0.9	17
15	Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site. Cancer Immunology, Immunotherapy, 2016, 65, 1223-1231.	2.0	3
16	Immunotherapy in prostate cancer: challenges and opportunities. Immunotherapy, 2016, 8, 69-77.	1.0	14
17	Personalized Peptide Vaccine. , 2016, , 143-158.		0
18	Prospect and progress of personalized peptide vaccinations for advanced cancers. Expert Opinion on Biological Therapy, 2016, 16, 689-698.	1.4	14

#	ARTICLE	IF	CITATIONS
19	A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 151-160.	2.0	57
20	An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 54-60.	3.2	44
21	Identification of novel L-derived T helper epitope long peptides applicable for HLA-A*2⁺ cancer patients as cancer vaccine. <i>Cancer Science</i> , 2015, 106, 1493-1498.	1.7	5
22	Assessment of cell proliferation in renal cell carcinoma using dual-phase 18F-fluorodeoxyglucose PET/CT. <i>Oncology Letters</i> , 2015, 10, 822-828.	0.8	9
23	Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients. <i>Journal of Immunology Research</i> , 2015, 2015, 1-8.	0.9	14
24	Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 493-505.	2.0	19
25	Reduced expression of erythropoietin-producing hepatocyte B6 receptor tyrosine kinase in prostate cancer. <i>Oncology Letters</i> , 2015, 9, 1672-1676.	0.8	10
26	Haptoglobin promoter polymorphism rs5472 as a prognostic biomarker for peptide vaccine efficacy in castration-resistant prostate cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1565-1573.	2.0	8
27	Immunological evaluation of peptide vaccination for cancer patients with the HLA A*26 allele. <i>Cancer Science</i> , 2015, 106, 1257-1263.	1.7	7
28	Personalized Peptide Vaccine for Treatment of Advanced Cancer. <i>Current Medicinal Chemistry</i> , 2014, 21, 2332-2345.	1.2	46
29	Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 919-929.	2.0	80
30	A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time. <i>BMC Cancer</i> , 2013, 13, 613.	1.1	17
31	Next-generation peptide vaccines for advanced cancer. <i>Cancer Science</i> , 2013, 104, 15-21.	1.7	108
32	Current status of immunotherapy for the treatment of biliary tract cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1069-1072.	1.4	18
33	A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients. <i>Oncology Reports</i> , 2013, 30, 1094-1100.	1.2	50
34	Personalized Peptide Vaccine as a Novel Immunotherapy Against Advanced Cancer. , 2013, , 361-369.		0
35	Personalized peptide vaccination in patients with refractory non-small cell lung cancer. <i>International Journal of Oncology</i> , 2012, 40, 1492-500.	1.4	25
36	Personalized peptide vaccination: A novel immunotherapeutic approach for advanced cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1309-1313.	1.4	26

#	ARTICLE	IF	CITATIONS
37	Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. <i>Prostate</i> , 2012, 72, 834-845.	1.2	37
38	Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination. <i>Cancer</i> , 2012, 118, 3208-3221.	2.0	32
39	Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 109-117.	0.8	3
40	A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. <i>BJU International</i> , 2011, 108, 831-838.	1.3	20
41	Exploring immune therapy for renal cancer. <i>International Journal of Urology</i> , 2011, 18, 412-421.	0.5	0
42	A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A*24-positive patients with castration-resistant prostate cancer. <i>Prostate</i> , 2011, 71, 470-479.	1.2	34
43	A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. <i>Oncology Reports</i> , 2010, 24, 795-801.	1.2	64
44	A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1001-1009.	2.0	99
45	A β -tubulin 5-derived peptide induces cytotoxic T lymphocytes restricted to the HLA-A24 allele in prostate cancer patients. <i>Experimental and Therapeutic Medicine</i> , 2010, 1, 833-839.	0.8	1
46	Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. <i>Cancer Biology and Therapy</i> , 2010, 10, 1266-1279.	1.5	46
47	Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines. <i>European Journal of Cancer</i> , 2010, 46, 1514-1519.	1.3	34
48	Personalized peptide vaccination for urological cancer. <i>Drug Delivery System</i> , 2010, 25, 103-109.	0.0	0
49	An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1877-1885.	2.0	9
50	Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients. <i>Prostate</i> , 2008, 68, 1753-1762.	1.2	15
51	Effect of an extract of <i>Ganoderma lucidum</i> in men with lower urinary tract symptoms: a double-blind, placebo-controlled randomized and dose-ranging study. <i>Asian Journal of Andrology</i> , 2008, 10, 651-658.	0.8	23
52	Randomized clinical trial of an ethanol extract of <i>Ganoderma lucidum</i> in men with lower urinary tract symptoms. <i>Asian Journal of Andrology</i> , 2008, 10, 777-785.	0.8	35
53	A randomized clinical trial of suspension technique for improving early recovery of urinary continence after radical retropubic prostatectomy. <i>BJU International</i> , 2008, 102, 958-963.	1.3	42
54	Recent Advances in Cancer Vaccines: An Overview. <i>Japanese Journal of Clinical Oncology</i> , 2008, 39, 73-80.	0.6	62

#	ARTICLE	IF	CITATIONS
55	Bilateral Neurovascular Bundles Sparing Prostatectomy Preserves Sexual Function in Patients with Localized Prostate Cancer. <i>Kurume Medical Journal</i> , 2008, 55, 63-69.	0.0	1
56	New Peptide Vaccine Candidates for Epithelial Cancer Patients With HLA-A3 Supertype Alleles. <i>Journal of Immunotherapy</i> , 2007, 30, 274-281.	1.2	17
57	Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. <i>Prostate</i> , 2007, 67, 933-942.	1.2	44
58	Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients. <i>Cancer Science</i> , 2007, 98, 1965-1968.	1.7	36
59	Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 689-698.	2.0	32
60	Development of a virtual needle biopsy simulation system for the virtual prostate. <i>Systems and Computers in Japan</i> , 2006, 37, 93-104.	0.2	2
61	Urodynamic evaluation of a suspension technique for rapid recovery of continence after radical retropubic prostatectomy. <i>International Journal of Urology</i> , 2006, 13, 373-378.	0.5	35
62	Evaluation of a prostate biopsy strategy for cancer detection using a computer simulation system with virtual needle biopsy for three-dimensional prostate models. <i>International Journal of Urology</i> , 2006, 13, 1296-1303.	0.5	2
63	A questionnaire survey of patient preparation and techniques for prostate biopsy among urologists in the Kyushu and Okinawa regions of Japan. <i>International Journal of Clinical Oncology</i> , 2006, 11, 390-395.	1.0	7
64	Combination Therapy of Personalized Peptide Vaccination and Low-Dose Estramustine Phosphate for Metastatic Hormone Refractory Prostate Cancer Patients: An Analysis of Prognostic Factors in the Treatment. <i>Oncology Research</i> , 2006, 16, 341-349.	0.6	35
65	Vaccination of Cytotoxic T Lymphocyte-Directed Peptides Elicited and Spread Humoral and Th1-Type Immune Responses to Prostate-Specific Antigen Protein in a Prostate Cancer Patient. <i>Journal of Immunotherapy</i> , 2005, 28, 368-375.	1.2	16
66	New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients. <i>Prostate</i> , 2005, 62, 233-242.	1.2	13
67	Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. <i>Prostate</i> , 2005, 63, 1-12.	1.2	58
68	Identification of Peptide Vaccine Candidates for Prostate Cancer Patients with HLA-A3 Supertype Alleles. <i>Clinical Cancer Research</i> , 2005, 11, 6933-6943.	3.2	42
69	Humoral Responses to Peptides Correlate with Overall Survival in Advanced Cancer Patients Vaccinated with Peptides Based on Pre-existing, Peptide-Specific Cellular Responses. <i>Clinical Cancer Research</i> , 2004, 10, 929-937.	3.2	109
70	Early catheter removal 3 days after radical retropubic prostatectomy. <i>International Journal of Urology</i> , 2004, 11, 983-988.	0.5	24
71	Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. <i>International Journal of Urology</i> , 2004, 11, 103-109.	0.5	28
72	Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer. <i>Cancer Science</i> , 2004, 95, 77-84.	1.7	44

#	ARTICLE	IF	CITATIONS
73	Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2 + patients with hormone-refractory prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 479-489.	2.0	40
74	Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. <i>Prostate</i> , 2004, 60, 32-45.	1.2	30
75	A prostate stem cell antigen-derived peptide immunogenic in HLA-A24? prostate cancer patients. <i>Prostate</i> , 2004, 60, 205-213.	1.2	22
76	Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients. <i>Prostate</i> , 2004, 60, 273-281.	1.2	32
77	Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients. <i>Oncology Reports</i> , 2004, 12, 601.	1.2	5
78	Suspension Technique Improves Rapid Recovery of Urinary Continence Following Radical Retropubic Prostatectomy. <i>Kurume Medical Journal</i> , 2004, 51, 245-251.	0.0	14
79	Target molecules in specific immunotherapy against prostate cancer. <i>International Journal of Clinical Oncology</i> , 2003, 8, 193-199.	1.0	26
80	Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. <i>Prostate</i> , 2003, 57, 80-92.	1.2	106
81	Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients. <i>Prostate</i> , 2003, 57, 152-159.	1.2	47
82	Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients. <i>Cancer Science</i> , 2003, 94, 622-627.	1.7	35
83	Prognostic Factors for Multifocal Prostate Cancer in Radical Prostatectomy Specimens: Lack of Significance of Secondary Cancers. <i>Journal of Urology</i> , 2003, 170, 459-463.	0.2	206
84	Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. <i>Urology</i> , 2003, 61, 993-998.	0.5	33
85	Peptide Vaccination for Patients With Melanoma and Other Types of Cancer Based on Pre-existing Peptide-Specific Cytotoxic T-Lymphocyte Precursors in the Periphery. <i>Journal of Immunotherapy</i> , 2003, 26, 357-366.	1.2	46
86	Transurethral Electrovaporization for Giant Prostatic Hyperplasia: Report of a Case. <i>Kurume Medical Journal</i> , 2003, 50, 151-153.	0.0	6
87	No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer. <i>Oncology Reports</i> , 2002, 9, 1075-80.	1.2	7
88	INDUCTION OF TUMOR SPECIFIC CYTOTOXIC T LYMPHOCYTES IN PROSTATE CANCER USING PROSTATIC ACID PHOSPHATASE DERIVED HLA-A2402 BINDING PEPTIDE. <i>Journal of Urology</i> , 2001, 166, 1508-1513.	0.2	40
89	PYRIDINOLINE CROSS-LINKED CARBOXYTERMINAL TELOPEPTIDE OF TYPE I COLLAGEN AS A USEFUL MARKER FOR MONITORING METASTATIC BONE ACTIVITY IN MEN WITH PROSTATE CANCER. <i>Journal of Urology</i> , 2001, 166, 1106-1110.	0.2	30
90	RELATIONSHIP BETWEEN SYSTEMATIC BIOPSIES AND HISTOLOGICAL FEATURES OF 222 RADICAL PROSTATECTOMY SPECIMENS: LACK OF PREDICTION OF TUMOR SIGNIFICANCE FOR MEN WITH NONPALPABLE PROSTATE CANCER. <i>Journal of Urology</i> , 2001, 166, 104-110.	0.2	222

#	ARTICLE	IF	CITATIONS
91	Assessment of morphometric measurements of prostate carcinoma volume. <i>Cancer</i> , 2000, 89, 1056-1064.	2.0	99
92	AN ANALYSIS OF 148 CONSECUTIVE TRANSITION ZONE CANCERS: CLINICAL AND HISTOLOGICAL CHARACTERISTICS. <i>Journal of Urology</i> , 2000, 163, 1751-1755.	0.2	151
93	PREOPERATIVE SERUM PROSTATE SPECIFIC ANTIGEN DOES NOT REFLECT BIOCHEMICAL FAILURE RATES AFTER RADICAL PROSTATECTOMY IN MEN WITH LARGE VOLUME CANCERS. <i>Journal of Urology</i> , 2000, 164, 1596-1600.	0.2	42
94	Necessity of repeat biopsies in men for suspected prostate cancer. <i>International Journal of Urology</i> , 1999, 6, 7-12.	0.5	29